N/A N=53 Evaluation of 3D Visualization for Total Colectomy
Ulcerative Colitis
Primary: Operating Time — 75.3; 82.7 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=407 Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Nasal Polyps
Primary: Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 52 — 0.0; -1.0 Scores on a scale — p=<0.001
N/A N=21 The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars
Acne Scars
Primary: Percentage of Participants With Facial Acne Improvement Using the Global Aesthetic Improvement Scale — 28.6; 57.1; 14.3 percentage of participants
N/A N=42 Rifaximin in Minimal Hepatic Encephalopathy
Hepatic Encephalopathy
Primary: Driving Performance — 7.6; 5.5 raw number of driving errors
Phase 3 N=65 8-Week Atopic Dermatitis (AD) Treatment Study
Atopic Dermatitis Eczema
Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05
Phase 2 N=86 FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Hepatocellular Carcinoma (HCC) · Solid Malignancies
Primary: Number of Participants With Dose-limiting Toxicity (DLT): Phase I Only — 10.0; 0; 0; 4.3 Percentage of participants
N/A N=30 Imaging Brain Tumors With FACBC and Methionine
Brain Cancer · CNS Cancer
Primary: Maximum Standardized Uptake Value of 3-[18F]-FACBC — 4.5 SUVmax
Phase 3 N=594 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Primary: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to…
Phase 2 N=28 Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients
Effect of Drugs
Primary: Objective Response Rate (ORR) Before First PD — 60.7 Percentage of Participants
Phase 2 N=7 Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
Carcinoma, Renal Cell
Primary: Change in Relative VO2 Peak From Baseline to Week 12 in the 4/2 and 2/1 Sunitinib Administration Schedules — -1.13; 1.27 mL/kg/min
Phase 2 N=49 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia
Sickle Cell Anemia
Primary: Change From Baseline of 4- Week Average Daily Pain Measured by Visual Analog Score (VAS) Over the Period of Week 8 to 12 — -0.45; -0.37 Score on a scale — p=0.55
N/A N=112 Developing an Activity Pacing Framework: Feasibility and Acceptability
Chronic Pain · Fibromyalgia · Chronic Fatigue Syndrome
Primary: Change in Activity Pacing Questionnaire (APQ-28) From Baseline to the End of the 6-week's Programme — 0.70; 0.99; 0.84; 0.67 score on a scale
N/A N=156 Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
Prosthetic Joint Infection
Primary: Calprotectin POC — 1; 3; 52; 29 Participants
N/A N=20 A Study for the Assessment of the Benefits of a Novel Mesh Nebulizer in the Treatment of Patients With Stable COPD
COPD
Primary: Device Preference Among the Number of Participants. — 17; 0 Participants — p=<0.001
Phase 3 N=751 A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
Facial Papulopustular Rosacea
Primary: The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 — 17.56; 15.34 Lesions — p=0.0031